Method of increasing the function of an AAV vector
A method of correcting singletons in a selected AAV sequence in order to increasing the packaging yield, transduction efficiency, and/or gene transfer efficiency of the selected AAV is provided. This method involves altering one or more singletons in the parental AAV capsid to conform the singleton to the amino acid in the corresponding position(s) of the aligned functional AAV capsid sequences.
1. A recombinant adeno-associated virus (AAV) having an AAV capsid comprising Clade A vp1 capsid proteins having the amino acid sequence of 1 to 736 of SEQ ID NO:29 with a F129L modification, Clade A vp2 proteins and Clade A vp3 proteins, wherein said recombinant further comprises, packaged within the capsid, a nucleic acid molecule comprising at least one AAV inverted terminal repeat (ITR) and a non-AAV nucleic acid sequence encoding a gene product operably linked to sequences which direct expression of the gene product in a host cell.
2. The recombinant AAV of claim 1 in which the gene product comprises cystic fibrosis transmembrane regulator (CFTR).
3. The recombinant AAV of claim 1 in which the at least one ITR is from AAV2.
4. A pharmaceutical composition comprising the recombinant AAV of claim 1 , and a pharmaceutically acceptable carrier.
5. The pharmaceutical composition of claim 4 , wherein the composition is formulated for delivery of the gene product to the lung airway epithelium.
6. The pharmaceutical composition of claim 4 , in which the gene product comprises cystic fibrosis transmembrane regulator (CFTR).
7. The pharmaceutical composition of claim 4 , in which the at least one ITR is from AAV2.